FDA Drug Recalls
676 recalls · Class II, newest first
Class II · Moderate risk Ongoing Jul 9, 2025
Reason CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Class II · Moderate risk Ongoing Jul 9, 2025
Reason CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 7, 2025
Reason Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Class II · Moderate risk Ongoing Jul 5, 2025
Reason Defective Container: spike of the cap becomes lodged in the nozzle of the product bottle.
Class II · Moderate risk Terminated Jul 2, 2025
Reason Labeling: Incorrect or Missing Lot and/or Exp Date: released with wrong expiry date as Feb.2027 instead of Jan.2027
Class II · Moderate risk Ongoing Jul 1, 2025
Reason Lack of Processing Controls; prescriptions were compounded in an ISO-5 area where it was identified that a daily cleaning step was not sufficiently…
Class II · Moderate risk Ongoing Jun 30, 2025
Reason Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.
Class II · Moderate risk Ongoing Jun 30, 2025
Reason Presence of foreign tablets/capsules: presence of foreign Divalproex Sodium Extended-Release 250mg tablet in a bottle of omeprazole capsules.
Class II · Moderate risk Ongoing Jun 30, 2025
Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Class II · Moderate risk Terminated Jun 27, 2025
Reason Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation…
Class II · Moderate risk Ongoing Jun 24, 2025
Reason Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH)…
Class II · Moderate risk Ongoing Jun 20, 2025
Reason Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets…
Class II · Moderate risk Ongoing Jun 20, 2025
Reason Subpotent Drug: Assay below the approved specification
Class II · Moderate risk Ongoing Jun 20, 2025
Reason Subpotent Drug: Assay below the approved specification
Class II · Moderate risk Ongoing Jun 20, 2025
Reason Subpotent Drug: Assay below the approved specification
Class II · Moderate risk Ongoing Jun 20, 2025
Reason Subpotent Drug: Assay below the approved specification
Class II · Moderate risk Ongoing Jun 20, 2025
Reason Subpotent Drug: Assay below the approved specification
Class II · Moderate risk Ongoing Jun 20, 2025
Reason Subpotent Drug: Assay below the approved specification
Class II · Moderate risk Ongoing Jun 20, 2025
Reason Subpotent Drug: Assay below the approved specification
Class II · Moderate risk Ongoing Jun 19, 2025
Reason Defective container; blister packaging inadequately sealed.